Biologics Distributor for Pain Medicine Practices in Kansas City

Documentation practices request before ordering

Pain medicine and physical medicine practices that add a regenerative biologics product typically request the same baseline documents as other specialties: a certificate of analysis for the lot being considered, a donor eligibility and screening summary, and, for exosome products, the analytical characterization data reported by the supplier. These documents support internal purchasing and compliance review rather than clinical decision-making, which remains with the treating physician and their counsel.

Confirming regulatory posture with your medical board

Missouri practices should confirm with the Missouri state medical board and their own legal counsel how a given product's intended use is classified under federal and state rules before incorporating it into a practice. Precision Biologics does not provide clinical, dosing or procedural guidance; our role is limited to supplying documented product and supporting the account verification and paperwork trail a practice needs for that internal review.

Receiving cold-chain and shelf-stable shipments

Cryopreserved Wharton's jelly products are shipped overnight on dry ice in validated containers and require immediate transfer to -80 degree C storage on arrival. Lyophilized exosome and Wharton's jelly formats are shelf-stable and do not require freezer capacity, which some practices find easier to receive and log by lot at the front desk rather than in a clinical freezer.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.